Scotia Capital’s Editas Medicine EDIT Stock Holding History

Scotia Capital’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-25,543	Closed	-$1.05M	–	885
2021 Q3	$1.05M	Buy	25,543 +768	+3%	+$42.1K	0.01%	503
2021 Q2	$1.4M	Buy	24,775 +815	+3%	+$30.1K	0.01%	449
2021 Q1	$1.01M	Buy	+23,960	New	+$1.36M	0.01%	484

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Scotia Capital's EDIT Position: Q4 2021 in Review

Scotia Capital sold out of Editas Medicine (EDIT) in Q4 2021, closing a stake of 25,543 shares — an estimated $1.05M sold.

Scotia Capital first reported a position in EDIT in Q1 2021 and held it in 3 quarters. The position peaked at $1.4M in Q2 2021. 305 funds tracked by Wall St. Rank hold EDIT as of Q4 2021.

Scotia Capital reported no remaining Editas Medicine position as of Q4 2021 after selling out during the quarter.
Scotia Capital sold 25,543 Editas Medicine shares in Q4 2021, an estimated $1.05M.
Scotia Capital first reported a position in Editas Medicine in Q1 2021 and held it in 3 quarters.
Scotia Capital's Editas Medicine position peaked at $1.4M in Q2 2021.
305 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2021.

Based on Scotia Capital's 13F filing for Q4 2021, filed 11 Feb 2022.